Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Sphera Funds Management LTD.

Sphera Funds Management LTD. decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 22.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 98,921 shares of the biotechnology company's stock after selling 27,925 shares during the period. Sarepta Therapeutics comprises approximately 2.2% of Sphera Funds Management LTD.'s holdings, making the stock its 10th largest holding. Sphera Funds Management LTD. owned approximately 0.10% of Sarepta Therapeutics worth $12,028,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in SRPT. Louisiana State Employees Retirement System lifted its stake in Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock worth $3,222,000 after acquiring an additional 100 shares during the period. EP Wealth Advisors LLC lifted its position in shares of Sarepta Therapeutics by 2.2% in the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock worth $606,000 after purchasing an additional 105 shares during the period. Manchester Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares in the last quarter. UMB Bank n.a. increased its holdings in Sarepta Therapeutics by 36.0% during the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock valued at $63,000 after buying an additional 138 shares during the period. Finally, CIBC Asset Management Inc lifted its holdings in Sarepta Therapeutics by 5.1% during the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after buying an additional 139 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Analyst Upgrades and Downgrades

SRPT has been the subject of several recent research reports. Needham & Company LLC reduced their price target on Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada reduced their target price on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group lowered their price target on shares of Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. HC Wainwright cut their price objective on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Finally, Guggenheim decreased their target price on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $122.61.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded up $0.52 during midday trading on Wednesday, reaching $40.51. The company's stock had a trading volume of 5,799,117 shares, compared to its average volume of 1,754,726. The firm has a market capitalization of $3.98 billion, a PE ratio of 32.12 and a beta of 0.85. The stock has a fifty day moving average of $57.70 and a 200 day moving average of $96.19. Sarepta Therapeutics, Inc. has a twelve month low of $34.10 and a twelve month high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The business's quarterly revenue was up 80.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.73 EPS. On average, equities analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.